Value
7.4/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 5.1 |
| Analyst target | 9.0 |
- ▸Attractively valued
FDMT · Why this verdict
Why 4D Molecular Therapeutics (FDMT) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.2/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Short interest of 29% is flagged as justified alongside elevated implied volatility (112%), reflecting the market's binary-outcome risk pricing. Risk breakdown | Short interest should fall below 20% and implied volatility should compress below 80% over the next 12 months as trial-outcome uncertainty resolves. | →Stable |
| CounterHigh justified short interest in binary biotech names often persists right up to a catalyst event and isn't necessarily predictive of the outcome. | ||
Quality score of 2.1 sits below the engine's 4.0 floor, driven by severe cash burn (FCF -79% of revenue) and a weak Piotroski F-Score of 3/9. Quality breakdown | Quality score should rise above 4.0 over the next 12 months as cash burn narrows or the Piotroski F-Score improves. | →Stable |
| CounterClinical-stage gene-therapy biotechs are expected to burn cash pre-commercialization, so a low quality score may not indicate business deterioration. | ||
The stock clears the V9 asymmetry gate with a strong 5.92 ratio and 88.9% upside, and screens as attractively valued on a price-to-sales basis. Reward-to-risk math | The asymmetry ratio should stay above 1.5 and upside_pct should remain above 50% over the next 12 months. | →Stable |
| CounterLight analyst coverage means the upside estimate rests on thin sourcing and could shift sharply on a single analyst revision. | ||
Insiders have sold $1.34M, 0.197% of market cap, in the past 90 days, triggering a MODERATE insider gate warning. Insider breakdown | Insider selling should fall back under the moderate threshold, below 0.15% of market cap, over the next 12 months, or reverse to net buying. | →Stable |
| CounterInsider sales at pre-revenue biotechs are frequently pre-scheduled selling plans (Rule 10b5-1) tied to personal liquidity needs rather than a signal about trial outcomes. | ||
The company ranks as an industry growth leader on the peer_rank growth dimension, a relative strength despite its low overall quality score. Notes | The growth peer rank should remain in the top decile over the next 12 months. | →Stable |
| CounterA high growth peer rank in a small, volatile biotech peer set can be driven by a single pipeline readout rather than durable underlying growth. | ||
Short interest of 29% is flagged as justified alongside elevated implied volatility (112%), reflecting the market's binary-outcome risk pricing.
→StableRisk breakdown
- Expectation
- Short interest should fall below 20% and implied volatility should compress below 80% over the next 12 months as trial-outcome uncertainty resolves.
CounterHigh justified short interest in binary biotech names often persists right up to a catalyst event and isn't necessarily predictive of the outcome.
Quality score of 2.1 sits below the engine's 4.0 floor, driven by severe cash burn (FCF -79% of revenue) and a weak Piotroski F-Score of 3/9.
→StableQuality breakdown
- Expectation
- Quality score should rise above 4.0 over the next 12 months as cash burn narrows or the Piotroski F-Score improves.
CounterClinical-stage gene-therapy biotechs are expected to burn cash pre-commercialization, so a low quality score may not indicate business deterioration.
The stock clears the V9 asymmetry gate with a strong 5.92 ratio and 88.9% upside, and screens as attractively valued on a price-to-sales basis.
→StableReward-to-risk math
- Expectation
- The asymmetry ratio should stay above 1.5 and upside_pct should remain above 50% over the next 12 months.
CounterLight analyst coverage means the upside estimate rests on thin sourcing and could shift sharply on a single analyst revision.
Insiders have sold $1.34M, 0.197% of market cap, in the past 90 days, triggering a MODERATE insider gate warning.
→StableInsider breakdown
- Expectation
- Insider selling should fall back under the moderate threshold, below 0.15% of market cap, over the next 12 months, or reverse to net buying.
CounterInsider sales at pre-revenue biotechs are frequently pre-scheduled selling plans (Rule 10b5-1) tied to personal liquidity needs rather than a signal about trial outcomes.
The company ranks as an industry growth leader on the peer_rank growth dimension, a relative strength despite its low overall quality score.
→StableNotes
- Expectation
- The growth peer rank should remain in the top decile over the next 12 months.
CounterA high growth peer rank in a small, volatile biotech peer set can be driven by a single pipeline readout rather than durable underlying growth.
TrendMatrix Research · core thesis
Engine thesis — one sentence
FDMT screens as a high-asymmetry, attractively-valued setup with industry-leading growth potential, but quality sits below the engine's floor on heavy cash burn, insiders have been notable sellers, and short interest plus implied volatility remain elevated ahead of binary trial catalysts.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
2.5/10data confidence 86%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 5.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -79% of revenue
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.8 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 1.1 |
- ▸Overbought (RSI 84)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.4/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 6.9 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (9.0) — signal dampened
- ▸Analyst upside: 117%
Insider
3.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Notable insider selling — $1,337,829 (0.201% of mkt cap)
Peer rank
6.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 6.3 |
| quality rank | 2.5 |
| growth rank | 10.0 |
- ▸Industry growth leader
Technical
4.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.1 |
| support resistance | 1.7 |
| 52w position | 8.6 |
Risk (lower is worse)
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 0.6 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| max pain risk | 7.0 |
| beta | 1.0 |
| debt equity | 9.8 |
- ▸High short interest justified: 29%
- ▸High IV: 241%
Catalyst
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Earnings concerns: 1B/3M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:6.8>=5.5
- ASYMMETRY:5.9>=1.5
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:34d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- INSIDER:0.20%=MODERATE
Reward-to-Risk
5.91
Upside
+88.6%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.7B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 7.4 could not lift the engine output above the verdict floor.
The strongest dimensions are Value at 7.4, Sentiment at 7.4, and Momentum at 6.8; the weakest are Quality at 2.5, Insider at 3.3, and Risk (lower is worse) at 3.6. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 5.91 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Quality Below Minimum Floor
Trip ifQuality score rises above 4.0, up from the current 2.1.
- P2High Asymmetry Attractive Valuation
Trip ifAsymmetry ratio falls below 1.5, down from the current 5.92.
- P3Notable Insider Selling
Trip ifInsider selling falls below 0.15% of market cap, down from the current 0.197%.
- P4High Short Interest And Implied Volatility
Trip ifShort interest falls below 20%, down from the current 29%.
- P5Industry Growth Leadership
Trip ifGrowth peer rank falls below the 50th percentile, down from the current top-decile ranking.